Omega-3 and omega-6 fatty acids: Roles in cardiometabolic disease

William S. Harris

Research output: Chapter in Book/Report/Conference proceedingChapter


Omega-3 and omega-6 FAs both have beneficial roles to play in reducing risk for cardiovascular disease (CVD). Although this is largely noncontroversial for the former FA family, some researchers have cautioned that the latter family may actually increase risk for CVD. This review will summarize the relevant human evidence, which shows that, in fact, both FA families are protective. The presumed “pro-inflammatory” nature of the omega-6 FAs (which is the basis for their hypothetical adverse effects) is not supported in a wide variety of human observational and interventional studies. The individual members of the omega-6 FA family can have completely opposing associations with risk; therefore there is no rational basis for summing all of the omega-6 FAs into a single metric and ascribing some health effect to the whole group. The primary omega-6 FA in the diet, linoleic acid, is associated with lower risk for both coronary heart disease and type 2 diabetes, hence lowering intakes (and thus blood levels) would be expected to raise, not lower, risk. Recommended intakes of linoleic acid in the 5%-10% range still apply. Most studies support the view that replacing saturated and trans fats in the diet with both the omega-6 and omega-3 FAs is the best overall strategy for reducing cardiometabolic risk.

Original languageEnglish (US)
Title of host publicationNutrition and Cardiometabolic Health
PublisherCRC Press
Number of pages16
ISBN (Electronic)9781498704274
ISBN (Print)9781498704267
StatePublished - Jan 1 2017

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Omega-3 and omega-6 fatty acids: Roles in cardiometabolic disease'. Together they form a unique fingerprint.

Cite this